Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma

Interventions

DRUG: Tebentafusp
DRUG: Tebentafusp with Pembrolizumab
DRUG: Investigators Choice

Sponsor

Immunocore Ltd